• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why PolyPid Dipped Over 73%; Here Are 60 Biggest Movers From Friday

    9/6/22 2:55:25 AM ET
    $AGRI
    $AMLX
    $AMPE
    $ARQT
    Metal Fabrications
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AGRI alert in real time by email

    Gainers

    • Venus Concept Inc. (NASDAQ:VERO) jumped 54.9% to settle at $0.5419 on Friday. The company, last month, posted downbeat quarterly results.
    • PaxMedica, Inc. (NASDAQ:PXMD) climbed 47.7% to settle at $5.17 on Friday. PaxMedica Executive Chairman, Director Michael Derby reported in Form4 filing the purchase of 95,000 shares at $5.25 per share.
    • Sunrise New Energy Co., Ltd. (NASDAQ:EPOW) gained 31.5% to close at $2.80.
    • Wheeler Real Estate Investment Trust, Inc. (NASDAQ:WHLR) jumped 26.9% to close at $2.65.
    • Rubius Therapeutics, Inc. (NASDAQ:RUBY) gained 23.4% to close at $0.9254. The company, last month, posted a narrower-than-expected quarterly loss.
    • Pear Therapeutics, Inc. (NASDAQ:PEAR) jumped 21.7% to close at $2.13.
    • Bright Minds Biosciences Inc. (NASDAQ:DRUG) rose 21.4% to close at $1.93. Bright Minds Biosciences recently initiated dosing in Phase I clinical trial of BMB-101 for Dravet Syndrome.
    • NewAge, Inc. (NASDAQ:NBEV) shares jumped 21.3% to close at $0.1482 on Friday on continued volatility after the company recently announced it filed a voluntary petition for relief under chapter 11 of the United States Bankruptcy Code. The stock is rebounding after trading lower on Thursday.
    • Liquidia Corporation (NASDAQ:LQDA) gained 20.6% to close at $5.86. Needham maintained Liquidia with a Buy and raised the price target from $12 to $16.
    • Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) surged 18.8% to close at $2.66.
    • Forza X1, Inc. (NASDAQ:FRZA) jumped 18.1% to close at $4.39.
    • United Maritime Corporation (NASDAQ:USEA) rose 17.4% to close at $1.42 after the company announced a $3 million buyback plan.
    • Hollysys Automation Technologies Ltd. (NASDAQ:HOLI) jumped 16.5% to close at $19.76. A consortium led by China's Hollysys Automation’s management aims to take the U.S.-listed automation and control system maker private in a deal at a $1.8 billion valuation, Reuters reported.
    • TScan Therapeutics, Inc. (NASDAQ:TCRX) jumped 16.4% to close at $3.27. TScan Therapeutics, last month, posted a Q2 loss of $0.63 per share.
    • Rain Therapeutics Inc. (NASDAQ:RAIN) rose 15.8% to settle at $5.50.
    • Aurora Innovation, Inc. (NASDAQ:AUR) gained 15.2% to close at $2.43 after the company's CEO reportedly said an Apple or Microsoft takeover was 'potentially appealing'
    • Werewolf Therapeutics, Inc. (NASDAQ:HOWL) jumped 14% to close at $6.93 after the company on Thursday initiated patient dosing in its Phase 1/1b trial of WTX-124.
    • DBV Technologies S.A. (NASDAQ:DBVT) surged 12.9% to close at $2.18. DBV Technologies, last month, posted a Q2 loss of $0.35 per share.
    • Borr Drilling Limited (NYSE:BORR) rose 12.6% to close at $4.46. Shares of several companies in the energy sector traded higher as investors await an OPEC+ meeting next week, in which an oil output cut might be discussed.
    • Smartsheet Inc. (NYSE:SMAR) gained 10.8% to close at $34.16 after the company reported better-than-expected Q2 sales results.
    • Cheetah Mobile Inc.. (NYSE:CMCM) shares gained 10.5% to close at $3.70 following effectiveness of its 1-for-5 reverse split.
    • nCino, Inc. (NASDAQ:NCNO) climbed 9.5% to close at $32.16 after the company reported better-than-expected Q2 adjusted EPS and sales results and issued Q3 and FY23 adjusted EPS and sales guidance above estimates.
    • Helmerich & Payne, Inc. (NYSE:HP) rose 8.5% to close at $44.45. Shares of several companies in the energy sector traded higher as investors await an OPEC+ meeting next week, in which an oil output cut might be discussed. Also, G7 nations agreed on a plan to cap Russian oil prices.
    • AMC Entertainment Holdings, Inc. (NYSE:APE) gained 8.3% to close at $4.97.
    • 5E Advanced Materials Inc. (NASDAQ:FEAM) rose 8.1% to close at $15.99.
    • HighPeak Energy, Inc. (NASDAQ:HPK) gained 8% to close at $26.35.
    • Ampio Pharmaceuticals, Inc. (NYSE:AMPE) rose 7.7% to close at $0.0992 after declining around 9% on Thursday.
    • AgriFORCE Growing Systems Ltd. (NASDAQ:AGRI) gained 7.1% to close at $1.95. The company announced the upcoming launch of un(Think) Awakened Flour.
    • Lululemon Athletica Inc. (NASDAQ:LULU) jumped 6.7% to settle at $314.17 as the company reported better-than-expected results for its second quarter and boosted its annual projections.
    • Okta, Inc. (NASDAQ:OKTA) gained 6.7% to close at $64.63. Guggenheim upgraded Okta from Sell to Neutral.

     

     

    Losers

    • PolyPid Ltd. (NASDAQ:PYPD) shares dipped 73.5% to close at $1.43 on Friday after the company announced its SHIELD I study did not achieve its primary endpoint of reduction in surgical site infections and mortality.
    • Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) tumbled 71.6% to settle at $14.90 amid post-IPO volatility.
    • Addentax Group Corp. (NASDAQ:ATXG) fell 68% to close at $9.59. Addentax shares tumbled 95% on Thursday following the company's uplisting and IPO.
    • ShiftPixy, Inc. (NASDAQ:PIXY) dropped 33.9% to settle at $13.60. ShiftPixy recently announced a 1-for-100 reverse stock split.
    • Hempacco Co., Inc. (NASDAQ:HPCO) fell 32.5% to close at $5.64 on post-IPO volatility.
    • Creatd, Inc. (NASDAQ:CRTD) declined 31.1% to settle at $0.3758. Creatd received delist decision and received 15 days to file appeal.
    • Virax Biolabs Group Limited (NASDAQ:VRAX) fell 28.9% to close at $5.64 after jumping 59% on Thursday.
    • Kuke Music Holding Limited (NYSE:KUKE) fell 27.4% to close at $0.82. The company, last month, reported Q2 results.
    • Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) declined 23.2% to close at $18.08 after a majority of FDA committee members voted the company's data for AMX0035 is not effective in the treatment of ALS patients.
    • IN8bio, Inc. (NASDAQ:INAB) fell 16.6% to close at $2.41. A Form 4 Filing recently showed Cavu Advisors purchased 51,214 shares at an average price of $2.02.
    • TDH Holdings, Inc. (NASDAQ:PETZ) fell 16.3% to close at $3.70.
    • TDH Holdings recently announced it acquired all of the equity interest of Beijing Wenxin Company from Kargo Services.
    • Calavo Growers, Inc. (NASDAQ:CVGW) dipped 15.9% to close at $35.09 after reporting downbeat Q3 earnings.
    • GigaCloud Technology Inc. (NASDAQ:GCT) fell 15.3% to settle at $20.04.
    • bioAffinity Technologies, Inc. (NASDAQ:BIAF) dipped 15.1% to close at $7.05 after jumping 36% on Thursday. The company priced its IPO at $6.125 per unit.
    • MDJM Ltd (NASDAQ:MDJH) dropped 13.1% to close at $1.86.
    • Reunion Neuroscience Inc. (NASDAQ:REUN) declined 12.7% to close at $3.02.
    • China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) fell 11.1% to settle at $1.20.
    • Vivani Medical, Inc. (NASDAQ:VANI) declined 11.1% to close at $3.52.
    • AMTD Digital Inc. (NYSE:HKD) fell 10.9% to close at $100.01.
    • Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) declined 10.3% to close at $24.11. Arcutis Biotherapeutics recently completed the enrollment of subject in its INTEGUMENT-2 pivotal Phase 3 trial of roflumilast cream 0.15% in adults and children with Atopic dermatitis (AD).
    • Vera Therapeutics, Inc. (NASDAQ:VERA) declined 10.2% to close at $19.21. Vera Therapeutics, last month, posted a Q2 loss of $0.55 per share.
    • Alpha Tau Medical Ltd. (NASDAQ:DRTS) dropped 9.9% to close at $6.68. Alpha Tau Medical recently posted a Q2 loss of $0.03 per share.
    • Pacific Biosciences of California, Inc. (NASDAQ:PACB) fell 9.7% to close at $5.32.
    • Ocugen, Inc. (NASDAQ:OCGN) dropped 8.4% to close at $2.40.
    • Peloton Interactive, Inc. (NASDAQ:PTON) fell 8.2% to close at $9.44. UBS maintained Peloton Interactive with a Sell and lowered the price target from $13 to $8.
    • Lands' End, Inc. (NASDAQ:LE) fell 7.6% to settle at $10.81. Lands' End recently issued Q3 EPS and sales and FY22 EPS guidance below estimates.
    • RiceBran Technologies (NASDAQ:RIBT) fell 5.8% to close at $2.58.
    • NIO Inc. (NYSE:NIO) fell 5.6% to settle at $17.73. Shares of Chinese companies traded lower amid lockdown measures in Chengdu as COVID-19 cases in China rise.
    • Array Technologies, Inc. (NASDAQ:ARRY) fell 5.6% to close at $20.27.
    • Meta Platforms, Inc. (NASDAQ:META) dropped 3.1% to close at $160.32. Meta Platforms agreed to use Qualcomm produced custom chipsets for its Quest virtual reality devices at Berlin's consumer electronics conference, Reuters reported.
    Get the next $AGRI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGRI
    $AMLX
    $AMPE
    $ARQT

    CompanyDatePrice TargetRatingAnalyst
    Okta Inc.
    $OKTA
    4/20/2026$90.00Equal Weight → Overweight
    Barclays
    Okta Inc.
    $OKTA
    4/16/2026$85.00Mkt Perform → Outperform
    Raymond James
    Bright Minds Biosciences Inc.
    $DRUG
    4/13/2026$145.00Buy
    Jefferies
    Meta Platforms Inc.
    $META
    4/10/2026$850.00 → $800.00Outperform
    Wolfe Research
    Meta Platforms Inc.
    $META
    4/9/2026$1144.00 → $1015.00Buy
    Rosenblatt
    Meta Platforms Inc.
    $META
    4/3/2026Buy → Hold
    Erste Group
    Meta Platforms Inc.
    $META
    4/2/2026Buy → Hold
    Erste Group
    nCino Inc.
    $NCNO
    4/1/2026$22.00Neutral → Overweight
    Piper Sandler
    More analyst ratings

    $AGRI
    $AMLX
    $AMPE
    $ARQT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Peloton Interactive, Inc. Announces Date of Third Quarter Fiscal 2026 Earnings Release and Conference Call

    NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Peloton Interactive, Inc. (NASDAQ:PTON) will release its third quarter fiscal 2026 financial results before the U.S. stock market opens on Thursday, May 7, 2026. The company will host a conference call and live audio webcast to discuss the financial results at 8:30 a.m. ET that day. Peloton's management will answer select questions from retail and institutional investors that are related to the company's business updates and quarterly financial results. If you would like to submit a question for consideration, please use the questionnaire form. A live audio webcast of the conference call will be available on the company's investor relations we

    4/23/26 4:05:00 PM ET
    $PTON
    Recreational Games/Products/Toys
    Consumer Discretionary

    Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane® (Nab-Paclitaxel)

    - IDE supplement expands trial to the other primary standard-of-care chemotherapy for pancreatic cancer patients, alongside mFOLFIRINOX - - IDE supplement also expands total trial size from 30 to 40 patients - - Study explores Alpha DaRT combined with chemotherapy in patients with newly diagnosed unresectable locally advanced or metastatic pancreatic adenocarcinoma - - This pilot study is a key part of Alpha Tau's broader strategy to bring Alpha DaRT to cancer patients with some of the highest unmet needs - JERUSALEM, April 23, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ:DRTS, DRTSW)) ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alp

    4/23/26 9:02:00 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Europe with Alpha DaRT® in French Multicenter ACAPELLA Clinical Trial

    ACAPELLA is the European multicenter clinical trial evaluating Alpha DaRT alpha-emitter radiotherapeutics combined with capecitabine for inoperable LAPC patients who have completed first-line mFOLFIRINOX, a population for whom no standard consolidation therapy exists and whose prognosis remains poor despite completing the best available systemic treatmentApproximately 30% of the estimated 140,000 Europeans diagnosed with pancreatic cancer each year present with locally advanced, inoperable, non-metastatic diseaseThe trial is a key pillar of Alpha Tau's global clinical expansion strategy in Europe, alongside the ongoing IMPACT multicenter pancreatic cancer trial in the United States First pat

    4/23/26 9:01:00 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    $AGRI
    $AMLX
    $AMPE
    $ARQT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bep Special Situations Iv Llc bought $8,000,000 worth of shares (4,000,000 units at $2.00) (SEC Form 4)

    4 - 5E Advanced Materials, Inc. (0001888654) (Issuer)

    2/4/26 4:30:07 PM ET
    $FEAM
    Mining & Quarrying of Nonmetallic Minerals (No Fuels)
    Industrials

    CFO Malm Joshua bought $7,500 worth of shares (3,750 units at $2.00), increasing direct ownership by 263% to 5,175 units (SEC Form 4)

    4 - 5E Advanced Materials, Inc. (0001888654) (Issuer)

    2/3/26 4:03:48 PM ET
    $FEAM
    Mining & Quarrying of Nonmetallic Minerals (No Fuels)
    Industrials

    Chief Executive Officer Weibel Paul Wesley Iii bought $7,500 worth of shares (3,750 units at $2.00), increasing direct ownership by 25% to 18,838 units (SEC Form 4)

    4 - 5E Advanced Materials, Inc. (0001888654) (Issuer)

    2/3/26 4:03:16 PM ET
    $FEAM
    Mining & Quarrying of Nonmetallic Minerals (No Fuels)
    Industrials

    $AGRI
    $AMLX
    $AMPE
    $ARQT
    SEC Filings

    View All

    SEC Form DEFA14A filed by Pacific Biosciences of California Inc.

    DEFA14A - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Filer)

    4/23/26 4:43:04 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form DEF 14A filed by Pacific Biosciences of California Inc.

    DEF 14A - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Filer)

    4/23/26 4:40:38 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 6-K filed by Alpha Tau Medical Ltd.

    6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)

    4/23/26 9:02:03 AM ET
    $DRTS
    Medical/Dental Instruments
    Health Care

    $AGRI
    $AMLX
    $AMPE
    $ARQT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ZORYVE issued to ARCUTIS BIOTHERAPEUTICS INC

    Submission status for ARCUTIS BIOTHERAPEUTICS INC's drug ZORYVE (ORIG-1) with active ingredient ROFLUMILAST has changed to 'Approval' on 12/15/2023. Application Category: NDA, Application Number: 217242, Application Classification: Type 3 - New Dosage Form

    12/19/23 3:40:08 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ZORYVE issued to ARCUTIS BIOTHERAPEUTICS INC

    Submission status for ARCUTIS BIOTHERAPEUTICS INC's drug ZORYVE (ORIG-1) with active ingredient ROFLUMILAST has changed to 'Approval' on 12/15/2023. Application Category: NDA, Application Number: 217242, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

    12/15/23 5:01:31 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    September 29, 2022 - FDA Approves New Treatment Option for Patients with ALS

    For Immediate Release: September 29, 2022 The U.S. Food and Drug Administration today approved Relyvrio (sodium phenylbutyrate/taurursodiol) to treat patients with amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig’s disease.  “This approval provides another important treatment option for ALS, a life-threatening disease that currently has no cure,” said Billy Dunn, M.D., director of the Off

    9/29/22 5:02:14 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGRI
    $AMLX
    $AMPE
    $ARQT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Okta upgraded by Barclays with a new price target

    Barclays upgraded Okta from Equal Weight to Overweight and set a new price target of $90.00

    4/20/26 8:21:07 AM ET
    $OKTA
    Computer Software: Prepackaged Software
    Technology

    Okta upgraded by Raymond James with a new price target

    Raymond James upgraded Okta from Mkt Perform to Outperform and set a new price target of $85.00

    4/16/26 7:58:53 AM ET
    $OKTA
    Computer Software: Prepackaged Software
    Technology

    Jefferies initiated coverage on Bright Minds Biosciences with a new price target

    Jefferies initiated coverage of Bright Minds Biosciences with a rating of Buy and set a new price target of $145.00

    4/13/26 8:51:07 AM ET
    $DRUG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGRI
    $AMLX
    $AMPE
    $ARQT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Olivan Javier

    4 - Meta Platforms, Inc. (0001326801) (Issuer)

    4/22/26 6:31:15 PM ET
    $META
    Computer Software: Programming Data Processing
    Technology

    SEC Form 4 filed by Kirol Charles Peter

    4 - PELOTON INTERACTIVE, INC. (0001639825) (Issuer)

    4/22/26 4:16:17 PM ET
    $PTON
    Recreational Games/Products/Toys
    Consumer Discretionary

    SEC Form 4 filed by Jeffs Roger

    4 - Liquidia Corp (0001819576) (Issuer)

    4/21/26 4:30:32 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGRI
    $AMLX
    $AMPE
    $ARQT
    Leadership Updates

    Live Leadership Updates

    View All

    lululemon Names Proven Brand Builder Heidi O'Neill as Chief Executive Officer

    O'Neill is a visionary, consumer-focused executive with more than three decades of experience leading brand strategy, product innovation, and operational execution on a global scale lululemon athletica inc. (NASDAQ:LULU) today announced that, following a comprehensive search process, the company's Board of Directors has unanimously approved the appointment of industry veteran Heidi O'Neill as the company's next Chief Executive Officer. Ms. O'Neill will start as CEO and join the Board effective September 8, 2026, and will be based in Vancouver. "Heidi is an inspiring leader and proven, consumer-driven brand strategist, with a rare ability to both imagine a new future for a brand and to c

    4/22/26 4:05:00 PM ET
    $LULU
    Apparel
    Consumer Discretionary

    Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales

    Mr. Taylor brings a strong track record launching multiple high-profile therapies, most recently serving as Senior Vice President, Sales at Arcutis Biotherapeutics (NASDAQ:ARQT), where he led U.S. sales efforts for ZORYVE®, a next-generation topical PDE4 inhibitor; previously, he held leadership roles at Incyte (NASDAQ:INCY) supporting the launch of OPZELURA® Mr. Taylor to lead Palvella's U.S. sales organization in preparation for the potential U.S. launch of QTORIN™ rapamycin for microcystic lymphatic malformations, a serious, rare, lifelong genetic disease affecting an estimated more than 30,000 diagnosed patients in the U.S. WAYNE, Pa., April 07, 2026 (GLOBE NEWSWIRE) -- Palvella Ther

    4/7/26 7:30:00 AM ET
    $ARQT
    $INCY
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch

    nCino Appoints Keith Kettell as Chief Revenue Officer to Lead Next Phase of Growth

    WILMINGTON, N.C., March 31, 2026 (GLOBE NEWSWIRE) -- nCino, Inc. (NASDAQ:NCNO), the leading provider of intelligent, best-in-class banking solutions, today announced the appointment of Keith Kettell as Chief Revenue Officer, effective April 1. Kettell brings more than two decades of experience building and scaling go-to-market organizations in the technology and financial services sectors. Earlier in his career, he spent seven years at Salesforce, where he was instrumental in building the company's financial services go-to-market from the ground up, growing it into Salesforce's largest and fastest-growing industry vertical. He went on to join PagerDuty's Senior Leadership Team, responsibl

    3/31/26 4:05:00 PM ET
    $NCNO
    Computer Software: Prepackaged Software
    Technology

    $AGRI
    $AMLX
    $AMPE
    $ARQT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by nCino Inc.

    SC 13D/A - nCino, Inc. (0001902733) (Subject)

    12/12/24 6:29:06 PM ET
    $NCNO
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13G/A filed by PolyPid Ltd.

    SC 13G/A - PolyPid Ltd. (0001611842) (Subject)

    12/12/24 7:05:07 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Wheeler Real Estate Investment Trust Inc.

    SC 13D/A - Wheeler Real Estate Investment Trust, Inc. (0001527541) (Subject)

    12/9/24 5:54:19 PM ET
    $WHLR
    Real Estate Investment Trusts
    Real Estate

    $AGRI
    $AMLX
    $AMPE
    $ARQT
    Financials

    Live finance-specific insights

    View All

    Peloton Interactive, Inc. Announces Date of Third Quarter Fiscal 2026 Earnings Release and Conference Call

    NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Peloton Interactive, Inc. (NASDAQ:PTON) will release its third quarter fiscal 2026 financial results before the U.S. stock market opens on Thursday, May 7, 2026. The company will host a conference call and live audio webcast to discuss the financial results at 8:30 a.m. ET that day. Peloton's management will answer select questions from retail and institutional investors that are related to the company's business updates and quarterly financial results. If you would like to submit a question for consideration, please use the questionnaire form. A live audio webcast of the conference call will be available on the company's investor relations we

    4/23/26 4:05:00 PM ET
    $PTON
    Recreational Games/Products/Toys
    Consumer Discretionary

    HighPeak Energy, Inc. Announces 2026 First Quarter Earnings Release and Conference Call Dates

    FORT WORTH, Texas, April 23, 2026 (GLOBE NEWSWIRE) -- HighPeak Energy, Inc. (NASDAQ:HPK) ("HighPeak Energy"), today announced that it plans to release its 2026 first quarter financial and operating results after the close of trading on Wednesday, May 6, 2026. HighPeak Energy will host a conference call and webcast on Thursday, May 7, 2026 at 10:00 a.m. Central Time for investors and analysts to discuss its 2026 first quarter financial results and operational highlights. Participants may register for the call here. Access to the live audio-only webcast and replay of the earnings release conference call may be found here. A live broadcast of the earnings conference call will also be availab

    4/23/26 6:05:00 AM ET
    $HPK
    Oil & Gas Production
    Energy

    Borr Drilling Limited - Invitation to Webcast and Conference Call for Q1 2026 Results

    HAMILTON, Bermuda, April 20, 2026 /PRNewswire/ -- Borr Drilling Limited (NYSE:BORR) and (Euronext Growth Oslo: BORR) (the "Company") plans to release its financial results for the first quarter of 2026 after the close of trading on NYSE on Wednesday, May 20, 2026. A conference call and webcast are scheduled for 09:00 New York time (15:00 CEST) on Thursday, May 21, 2026.The earnings report, webcast and accompanying presentation will be available on the Investor Relations section of the Company's website, www.borrdrilling.com.In order to listen to the live presentation, participants may do one of the following:a)    WebcastTo access the webcast, please go to the following link:https://edge.med

    4/20/26 3:29:00 AM ET
    $BORR
    Oil & Gas Production
    Energy